<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01127204</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 12206 MONOD</org_study_id>
    <secondary_id>IP.2007.33011.002</secondary_id>
    <nct_id>NCT01127204</nct_id>
  </id_info>
  <brief_title>Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age</brief_title>
  <official_title>Randomized Phase 3 Trial to Evaluate Two Simplified Antiretroviral Treatment Strategies in HIV Infected Children, Treated by Antiretroviral Triple Therapy Before One Year of Age, in Virological Success in Africa (Burkina Faso, Côte d'Ivoire, Rwanda)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European and Developing Countries Clinical Trials Partnership (EDCTP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Public Research Centre Health, Luxembourg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Foreign Affairs, Luxembourg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ouagadougou, Burkina Faso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Rwanda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut de Sante Publique, d'Epidémiologie et de Développement</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Paris 5 - Rene Descartes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen Fabiola Children's University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MONOD trial aim to evaluate the implementation of early antiretroviral treatment&#xD;
      strategies in HIV-infected infants and assess the feasibility and efficacy of simplifying the&#xD;
      initial proposed regimen after a successful one year treatment. The initial treatment is&#xD;
      AZT-3TC-LPV/r twice a day. After one year, the children will be randomized in one of the&#xD;
      following : arm 1-reference AZT-3TC-LPV/r twice daily; arm 2-simplified ABC-3TC-EFV once&#xD;
      daily.&#xD;
&#xD;
      The perspective of this project is to identify antiretroviral strategies to improve treatment&#xD;
      access and adherence for children in sub-saharian Africa.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Initial therapeutic cohort: Virological success</measure>
    <time_frame>12 months</time_frame>
    <description>survival without virological failure (death or loss of follow-up or virologic failure, i.e. HIV-ARN ≥400 copies/mL on one consecutive sample), analysis of resistance profile.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Randomised simplification phase: Virological success</measure>
    <time_frame>25 months</time_frame>
    <description>survival without virological failure (death or loss of follow-up or virologic failure (HIV-ARN ≥400 copies/mL ))from M13 to M25.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virological success</measure>
    <time_frame>12 months</time_frame>
    <description>HIV RNA &lt; 400 copies / mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological response</measure>
    <time_frame>12 and 25 months</time_frame>
    <description>CD4+ lymphocyte absolute count and percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiretroviral and cotrimoxazol pharmacokinetic parameters</measure>
    <time_frame>6, 19 and 25 months</time_frame>
    <description>The following parameters will be measured or calculated: maximal and minimal concentration (Cmax, Cmin), half life (t1/2), Aire Under the Curve (AUC), clearance and volume of distribution, for all antiretroviral (according to treatment arm : AZT, 3TC, LPV, ABC, EFV) and cotimoxazol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance</measure>
    <time_frame>12 and 25 month</time_frame>
    <description>occurence of grade 3 and 4 adverse events related to the trial treatment, particularly occurence of immune reconstitution inflammatory syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>12 and 25 months</time_frame>
    <description>measurement at each protocol visit of the three last days treatment intake to be corelated to the antiretroviral concentration and virological success</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resistance to antiretroviral</measure>
    <time_frame>12 and 25 months</time_frame>
    <description>Genotyping to analyse resistance mutation when virological failure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>arm 1 (reference strategy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AZT-3TC-LPV/r twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm 2 (simplification strategy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABC-3TC-EFV once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZT-3TC-LPV/r twice a day</intervention_name>
    <description>AZT sirup (10mg/ml): 4 mg/kg or 180 mg/m2 twice daily 3TC sirup (10mg/ml): 4 mg/kg twice daily LPV/r sirup (80/20 mg/ml): 12 mg/kg twice daily</description>
    <arm_group_label>arm 1 (reference strategy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABC-3TC-EFV once a day</intervention_name>
    <description>ABC sirup (20mg/ml): 16 mg/kg once daily in the morning 3TC sirup (10mg/ml): 8 mg/kg once daily in the morning EFV sirup (30mg/ml): 25 mg/kg once daily in the morning before food intake</description>
    <arm_group_label>arm 2 (simplification strategy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for antiretroviral treatment initiation:&#xD;
&#xD;
          -  infant follow-up in one of the trial site&#xD;
&#xD;
          -  HIV-1 infection diagnose by RT PCR after 6 weeks of life&#xD;
&#xD;
          -  age between 3 and 12 month at the antiretroviral treatment initiation&#xD;
&#xD;
          -  naive of antiretrovirals except if received for the prevention of mother to child HIV&#xD;
             transmission&#xD;
&#xD;
          -  HB&gt;=7 g/dl, neutrophiles&gt;750/mm3, creatinin&lt;3xULN, TGO and TGP&lt;3xULN&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
        Exclusion Criteria for antiretroviral treatment initiation:&#xD;
&#xD;
          -  HIV-2 infection or HIV-1/HIV-2 co-infection&#xD;
&#xD;
          -  Known intolerance to one of the trial treatment&#xD;
&#xD;
          -  HB&lt;7 g/dl, neutrophiles&lt;750/mm3, creatinin&gt;3xULN, TGO or TGP&gt;3xULN&#xD;
&#xD;
        Inclusion Criteria for randomisation at 12 months in the simplification phase:&#xD;
&#xD;
          -  age 24 months at most&#xD;
&#xD;
          -  virological success define as 2 consecutive indetectable HIV RNA measured by RT PCR at&#xD;
             least 3 months apart.&#xD;
&#xD;
        Exclusion Criteria for randomisation at 12 months in the simplification phase:&#xD;
&#xD;
          -  virological failure after the first 12 months of antiretroviral treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marguerite Timite-Konan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de pédiatrie - CHU Yopougon - Abidjan, Côte d'Ivoire</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jules Mugabo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Infectious Desease Control - Kigali, Rwanda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolas Meda</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Ouagadougou - Ouagadougou, Burkina Faso</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de maladies infectieuses - CHU Charles de Gaulle</name>
      <address>
        <city>Ouagadougou</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de pédiatrie - CHU Yalgado Ouedraogo</name>
      <address>
        <city>Ouagadougou</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEPREF</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSU abobo-Avocatier</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
    <country>Côte D'Ivoire</country>
  </location_countries>
  <removed_countries>
    <country>Rwanda</country>
  </removed_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>May 19, 2010</study_first_submitted>
  <study_first_submitted_qc>May 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2010</study_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Antiretroviral therapy</keyword>
  <keyword>Infant</keyword>
  <keyword>Sub Saharian Africa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

